Tag Archives: gastric cancer

October, 2018

24 October
Lonsurf Meets Primary and Secondary Endpoints in its Late-Stage Study in Patients with Refractory Metastatic Gastric Cancer

PARIS–(BUSINESS WIRE)–Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or …
Share

21 June
Servier and Taiho Announce Lonsurf Demonstrates Significant Overall Survival Benefit in Phase 3 Gastric Cancer Trial

PARIS–(BUSINESS WIRE)–Servier and Taiho Pharmaceutical Co., Ltd. today announced clinical data from the pivotal Phase III trial (TAGS) for LONSURF® (trifluridine and tipiracil, TAS-102) which showed significant improvement in overall survival (OS) for the treatment of patients with refractory metastatic gastric cancer (HR=0.69 [95% IC 0.56-0.85], p=0.0003). The median overall survival …
Share

18 January
Daiichi-Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer

TOKYO, BASKING RIDGE, N.J. and MUNICH, Jan. 18, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that updated phase 1 safety and efficacy data for DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), in a subgroup of patients with HER2-expressing gastric cancer previously treated with trastuzumab …
Share

15 December
Merck’s Keytruda Fails Late-Stage Study in Patients with Advanced Gastric Cancer

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal phase 3 KEYNOTE-061 trial investigating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a second-line treatment for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, did not meet its primary endpoint of overall …
Share

31 July
FDA to Review Teva and Celltrion’s BLA for Proposed Biosimilar to Herceptin

INCHEON, Republic of Korea & JERUSALEM–(BUSINESS WIRE)–Jul. 31, 2017– Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for CT-P6, a proposed Monoclonal Antibody (mAb) biosimilar to Herceptin®1 (INN: trastuzumab) which is used for the treatment of Human Epidermal …
Share

14 April
Study Finds Simple Breath Test Could Predict Stomach Cancer Risk

Scientists have discovered a new simple breath test that can detect and predict whether an individual is at risk for stomach cancer. A new technology that analyzes and interprets patients’ “breath prints” – unique patterns of molecules people breathe in and out and reflect conditions in the body – is …
Share